These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2627985)

  • 21. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
    Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Phase I-II study of recombinant interleukin-2].
    Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):903-13. PubMed ID: 3494427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
    Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
    Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2.
    Velotti F; Stoppacciaro A; Ruco L; Tubaro A; Pettinato A; Morrone S; Napolitano T; Bossola PC; Franks CR; Palmer P
    Cancer Res; 1991 May; 51(9):2456-62. PubMed ID: 2015606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
    J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in biochemical laboratory investigation in patients treated with constant infusion recombinant interleukin-2.
    Ubhi SS; Horsburgh T; Veitch PS; Bell PR
    Anticancer Res; 1991; 11(6):2059-62. PubMed ID: 1776840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
    Palmer PA; Atzpodien J; Philip T; Negrier S; Kirchner H; Von der Maase H; Geertsen P; Evers P; Loriaux E; Oskam R
    Cancer Biother; 1993; 8(2):123-36. PubMed ID: 7804353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells.
    Foon KA; Walther PJ; Bernstein ZP; Vaickus L; Rahman R; Watanabe H; Sweeney J; Park J; Vesper D; Russell D
    J Immunother (1991); 1992 Apr; 11(3):184-90. PubMed ID: 1515423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma.
    Lopez M; Carpano S; Cancrini A; Marcellini M; Del Medico P; Rinaldi M; Vici P; Paoletti G; Di Lauro L
    Ann Oncol; 1993 Sep; 4(8):689-91. PubMed ID: 8241001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor.
    Blay JY; Favrot MC; Negrier S; Combaret V; Chouaib S; Mercatello A; Kaemmerlen P; Franks CR; Philip T
    Cancer Res; 1990 Apr; 50(8):2371-4. PubMed ID: 2317822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.
    Abi-Aad AS; Figlin RA; Belldegrun A; deKernion JB
    J Immunother (1991); 1991 Aug; 10(4):292-5. PubMed ID: 1931865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-tumor effects of interleukin 2 against genitourinary cancer--basic study and clinical application].
    Marumo K
    Hum Cell; 1988 Mar; 1(1):65-70. PubMed ID: 3154016
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.
    Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
    Jpn J Cancer Res; 1988 Jan; 79(1):131-43. PubMed ID: 3128501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.